$1.90
5.94% yesterday
Nasdaq, Sep 26, 09:25 pm CET
ISIN
US58468P2065
Symbol
MNOV
Sector
Industry

MediciNova, Inc. Stock price

$1.89
+0.62 48.82% 1M
+0.53 38.97% 6M
+0.39 26.00% YTD
-0.21 10.00% 1Y
-2.07 52.27% 3Y
-5.81 75.45% 5Y
-0.97 33.92% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
-0.13 6.44%
ISIN
US58468P2065
Symbol
MNOV
Sector
Industry

Key metrics

Market capitalization $92.70m
Enterprise Value $48.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 48.85
P/S ratio (TTM) P/S ratio 92.70
P/B ratio (TTM) P/B ratio 1.61
Revenue (TTM) Revenue $1.00m
EBIT (operating result TTM) EBIT $-9.82m
Free Cash Flow (TTM) Free Cash Flow $-8.55m
Cash position $44.34m
EPS (TTM) EPS $-0.17
P/E forward negative
Short interest 0.45%
Show more

Is MediciNova, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

MediciNova, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast MediciNova, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast MediciNova, Inc.:

Buy
100%

Financial data from MediciNova, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1 1
-
100%
- Direct Costs 0.02 0.02
90% 90%
2%
0.98 0.98
567% 567%
98%
- Selling and Administrative Expenses 4.92 4.92
11% 11%
492%
- Research and Development Expense 5.85 5.85
22% 22%
585%
-9.80 -9.80
26% 26%
-980%
- Depreciation and Amortization 0.02 0.02
90% 90%
2%
EBIT (Operating Income) EBIT -9.82 -9.82
27% 27%
-982%
Net Profit -8.16 -8.16
34% 34%
-816%

In millions USD.

Don't miss a Thing! We will send you all news about MediciNova, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediciNova, Inc. Stock News

Neutral
GlobeNewsWire
17 days ago
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected fo...
Neutral
GlobeNewsWire
23 days ago
LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 s...
Neutral
GlobeNewsWire
28 days ago
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID c...
More MediciNova, Inc. News

Company Profile

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Head office United States
CEO Yuichi Iwaki
Employees 13
Founded 2000
Website www.medicinova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today